Trials / Completed
CompletedNCT01462786
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
Phase 1, Open-Label, Crossover, Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental and Abdominal Areas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Kythera Biopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to compare the pharmacokinetic profile of ATX-101 administered into subcutaneous fat in the submental area and abdomen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATX-101 | 2 mg/cm2 ATX-101 |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2011-11-01
- Completion
- 2011-12-01
- First posted
- 2011-10-31
- Last updated
- 2016-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01462786. Inclusion in this directory is not an endorsement.